Bilimsel çalışmalar

Doç. Dr. Mutlu Hızal

101 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Prognostic Importance of Albumin Globulin Ratio in Small Cell Lung Cancer

    Ankara Medical Journal, 2019

    DOI 10.17098/amj.651978 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  2. Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?

    PubMed, 2019

    PMID 31646779 2 atıf (OpenAlex) Kaynak: OpenAlex

  3. Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?

    Future Oncology, 2019

    DOI 10.2217/fon-2018-0503 PMID 30854890 Açık erişimli tam metinKaynak: OpenAlex

  4. Bazal Hücreli Kanserde Güncel Tedavi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2019

    Kaynak: OpenAlex

  5. EP1.04-17 The Association of Clinicopathologic Features and Peripheral Blood Parameters with High PD-L1 Expression in Non-Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2019

    DOI 10.1016/j.jtho.2019.08.2145 Açık erişimli tam metinKaynak: OpenAlex

  6. Cilt Kanserleri

    AYBU AVESIS, 2019

    Kaynak: OpenAlex

  7. Evaluation of dynamic serum thiol/disulfide homeostasis in locally advanced and metastatic gastric cancer

    Journal of Oncological Sciences, 2018

    DOI 10.1016/j.jons.2018.01.002 8 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  8. P2.01-83 Evaluation of Dynamic Thiol/Disulphide Homeostasis in Advance Non-Small Cell Lung Cancer and Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2018

    DOI 10.1016/j.jtho.2018.08.1137 Açık erişimli tam metinKaynak: OpenAlex

  9. Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localization

    Journal of Cancer Research and Therapeutics, 2018

    DOI 10.4103/jcrt.jcrt_624_17 PMID 30880755 21 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  10. Mutational status of lung cancer patients and survival outcomes for patients with limited brain metastases.

    PubMed, 2018

    PMID 30722126 2 atıf (OpenAlex) Kaynak: OpenAlex

  11. Baş-Boyun Kanserlerinde Epidemiyoloji, Etiyoloji ve Evreleme

    Turkiye Klinikleri Medical Oncology - Special Topics, 2018

    Kaynak: OpenAlex

  12. Lokal İleri ve Metastatik Baş-Boyun Kanserlerinde Sistemik ve Hedeflenmiş Tedaviler

    Turkiye Klinikleri Medical Oncology - Special Topics, 2018

    Kaynak: OpenAlex

  13. Optimal Regimen For Treatment-Naive Hormone Receptor-Positive Her-2 Negative Metastatic Breast Cancer

    Future Oncology, 2018

    DOI 10.2217/fon-2018-0086 PMID 30484708 Açık erişimli tam metinKaynak: OpenAlex

  14. Diffüz Büyük B Hücreli Lenfomalarda CD30 Ekspresyon Sıklığı ve Klinikopatolojik Veriler ile İlişkisi

    AYBU AVESIS, 2018

    Kaynak: OpenAlex

  15. Efficacy of The Second-line Treatment in Metastatic Pancreas Cancer

    AYBU AVESIS, 2018

    Kaynak: OpenAlex

  16. The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)

    Annals of Oncology, 2017

    DOI 10.1093/annonc/mdx366.001 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  17. The association and prognostic significance of programmed death-ligand 1 (PD-L1) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM) patients.

    Journal of Clinical Oncology, 2017

    DOI 10.1200/jco.2017.35.15_suppl.e13536 1 atıf (OpenAlex) Kaynak: OpenAlex

  18. Do all aromatase inhibitors have similar efficacy and safety?

    Future Oncology, 2017

    DOI 10.2217/fon-2017-0228 PMID 28831832 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  19. Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer.

    Future Oncology, 2017

    DOI 10.2217/fon-2017-0270 PMID 28829190 8 atıf (OpenAlex) Kaynak: ORCID

  20. The current status of adjuvant treatment for high-risk renal cell carcinoma.

    Future Oncology, 2017

    DOI 10.2217/fon-2017-0352 PMID 28984480 Kaynak: ORCID

  21. Ferritin: Is it a Predictor of Prognosis in Myelodysplastic Syndrome?

    The World Clinics Journal of Medical Sciences, 2017

    DOI 10.5336/worldclin.2017-56274 Açık erişimli tam metinKaynak: OpenAlex

  22. The Role of Dynamic Serum Thiol-Disulphide Homeostasis in Metastatic Gastric Cancer

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  23. glioBlastome multiforme hastalarında pd-l1, pd-1, tümör infiltre eden lenfosit ve ıdh-1 gen mutasyon varlığının prognostik öneminin değerlendirilmesi

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  24. Glioblastome Multiforme Tanılı Hastalarda Eritrosit DağIlım Hacmi-Trombosit Oranının Sağ Kalım İle İlişkisi

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  25. ERkEn EvRE koloREktal kanSERlERdE RdW-platElEt oRanInIn pRognoStik önEMi

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  26. 2016 yIlInda tÜRkiyE kaynaklI onkolojik yayInlaR

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  27. ilERi EvRE koloREktal kanSERlERdE RdW-platElEt oRanInIn pRognoStik önEMi

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  28. The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastome multiforme(GBM)

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  29. t790M MutaSyonu pozitiF akciğER kanSERindE oSiMERtiniB diREnci; olgu SunuMu

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  30. Evaluation of dynamic serum thiol disulphide homeostasis in colorectal cancer

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  31. MEtaStatik vE nEoadjuvant tEdavi alan tRanSizyonEl HÜcREli MESanE kanSERindE HuMan EquiliBRativE nuclEoSidE tRanSpoRtER 1 (HEnt1) MolEkÜlÜnÜn pREdiktiF vE pRognoStik önEMinin dEğERlEndiRilMESi

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  32. kÜçÜk HÜcREli akciğER kanSERindE yEni pRogSnoStik BEliRtEç: alBuMin-gloBulin oRanI

    AYBU AVESIS, 2017

    Kaynak: OpenAlex

  33. Compare tumor features and survival in right sided and left sided early stage colorectal cancer

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  34. Effect of red cell disturbatıon width to platelet ratio on dısease free survival in early stage colorectal cancer

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  35. Effects of neutrophil lymphocyte ratio and platelet lymphocyte ratio on survival of non metastatic colorectal cancer

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  36. THE NEUTROPHIL LYMPHOC YTE RATIO MAY HAVE PROGNOSTICEFFECT IN THE METASTATIC COLORECTAL CANCER

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  37. EFFECT OF RED CELL DISTURBATION WIDTH TO PLATELET RATIO ONDISEASE FREE SURVIVAL IN EARLY STAGE COLORECTAL CANCER

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  38. THE PROGNOSTIC FACTORS IN STAGE 3 COLORECTAL CANCER PATIENTS

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  39. Association between tumor localisation andClinicopathologic characteristics and survival of colorectal cancer

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  40. Association between tumor localisation and clinicopathological characteristics and survival of colorectal cancer

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  41. Metastatic colorectal cancer survival İs there a difference between synchronous or metachronous tumors

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  42. A rare case metastatic anal cloacogenic transitional cell carcinoma

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  43. METASTATIC COLORECTAL CANCER SURVIVAL IS THERE A DIFFERENCEBETWEEN SYNCHRONOUS OR METACHRONOUS TUMORS

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  44. PROGNOSTIC IMPORTANCE RED CELL DISTURBATION WIDTH TOPLATELET RATIO IN ADVANCED COLORECTAL CANCER

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  45. Gastric cancer with lung metastasis and concurrent miliary tuberculosis

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  46. EFFECT OF THE RAS STATUS ON SURVIVAL IN ADVANCED COLON CANCER

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  47. ASSESSMENT OF THE COST EFFECTIVENESS OF THE FIRST LINE TARGETED THERAPIES FOR ADVANCED COLON CANCER IN TURKEY

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  48. ASSOSCIATION BETWEEN TUMOR LOCALISATION AND CLINICOPATHOLOGICAL CHARACTERISTICS AND SURVIVAL OF COLORECTAL CANCER

    AYBU AVESIS, 2016

    Kaynak: OpenAlex

  49. Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?

    Clinical Rheumatology, 2015

    DOI 10.1007/s10067-014-2854-1 PMID 25597616 12 atıf (OpenAlex) Kaynak: ORCID

  50. AB0194 Ll-37: A New Marker for Interstitial Lung Disease (ILD) in Systemic Sclerosis (SSC)?

    Annals of the Rheumatic Diseases, 2014

    DOI 10.1136/annrheumdis-2014-eular.2948 1 atıf (OpenAlex) Kaynak: OpenAlex